INmune Bio Inc. - Common stock (INMB)
INMB moved a median of 0.00% 30 minutes after news, and +0.67% by the close. How INMB actually reacts to news — the realized, point-in-time move the market made, measured across 286 labeled events over the last three years with zero look-ahead.
INMB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 278 |
| 30-min | 0.00% | 49% | 285 |
| 60-min | +0.56% | 54% | 285 |
| to close | +0.67% | 56% | 284 |
| Middle 50% of INMB reactions | -1.70% to +1.80% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 286 |
Half of all INmune Bio Inc. - Common stock news events land between -1.70% and +1.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How INMB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | -1.60% | 27% | +1.77% |
| Coverage initiations | 14 | -2.95% | 0% | -2.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how INMB ranks against every other measured name →
That’s how INMB usually reacts — get an email when it moves on news →Email me when INMB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INMB's baseline. Nothing else.
Recent INMB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™ | Press release | GlobeNewswire | -2.94% | -5.88% | |
| INmune Bio to Attend the 2026 Maxim Growth Summit | Press release | GlobeNewswire | +1.41% | -4.10% | |
| Form 8-K Inmune Bio, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +1.16% | -6.98% | |
| Form 8-K Inmune Bio, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -4.25% | -3.83% | |
| INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board | Press release | GlobeNewswire | +0.45% | +4.48% | |
| INmune Bio to Present at the H.C. Wainwright Global Investment Conference | Press release | GlobeNewswire | +0.00% | -2.38% | |
| INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings | Press release | GlobeNewswire | +2.08% | +1.88% | |
| Form 10-Q Inmune Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.78% | +5.84% | |
| INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress | Press release | GlobeNewswire | -1.78% | +5.84% | |
| Form 8-K Inmune Bio, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -2.83% | +4.52% | |
| INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th | Press release | GlobeNewswire | +0.73% | -1.13% | |
| INmune Bio Receives R&D Rebates of Approximately $4.6 Million | Press release | GlobeNewswire | +0.73% | -1.13% | |
| INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform | Press release | GlobeNewswire | +3.93% | +4.12% | |
| INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform | Press release | GlobeNewswire | +2.13% | +5.85% | |
| INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study | Press release | GlobeNewswire | -0.72% | -0.48% | |
| INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC | Press release | GlobeNewswire | +0.29% | +3.47% | |
| Form 8-K Inmune Bio, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +1.85% | +3.70% | |
| INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion | Press release | GlobeNewswire | +1.85% | +3.70% | |
| INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ | Press release | GlobeNewswire | +1.34% | +9.56% | |
| Form 8-K Inmune Bio, Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +5.59% | -5.59% | |
| INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB | Press release | GlobeNewswire | +1.44% | +2.16% | |
| Form 8-K Inmune Bio, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +2.65% | +9.85% | |
| Form 8-K Inmune Bio, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -2.18% | -7.04% | |
| INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial | Press release | GlobeNewswire | -0.70% | +0.00% | |
| INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform | Press release | GlobeNewswire | -0.90% | -6.63% | |
| Form 8-K Inmune Bio, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | -6.63% | |
| INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease | Press release | GlobeNewswire | -1.89% | +5.66% | |
| INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point | Press release | GlobeNewswire | -1.51% | +5.04% | |
| Form 10-Q Inmune Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.84% | +1.42% | |
| INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update | Press release | GlobeNewswire | +2.84% | +1.42% | |
| Biotech Leaders Launch National Alliance to Define the Future of American Innovation | Press release | Business Wire | +1.33% | +2.67% | |
| Form 8-K Inmune Bio, Inc. For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -1.30% | -1.30% | |
| INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases | Press release | GlobeNewswire | -1.30% | -1.30% | |
| INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th | Press release | GlobeNewswire | +2.25% | +7.52% | |
| Form DEF 14A Inmune Bio, Inc. For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +2.21% | |
| INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models | Press release | GlobeNewswire | +0.00% | +2.68% | |
| Form 10-K Inmune Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.90% | +1.80% | |
| INmune Bio Inc. Announces 2025 Results and Provides Business Update | Press release | GlobeNewswire | -0.90% | +1.80% | |
| INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. | Press release | GlobeNewswire | -0.80% | -2.48% | |
| INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease | Press release | GlobeNewswire | -2.44% | -0.81% | |
| Form 8-K Inmune Bio, Inc. For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -1.84% | -5.15% | |
| Form 8-K Inmune Bio, Inc. For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +0.78% | +4.69% | |
| INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar | Press release | GlobeNewswire | -1.54% | -3.08% | |
| Form 8-K Inmune Bio, Inc. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -0.76% | |
| INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB | Press release | GlobeNewswire | +2.68% | +1.15% | |
| Form 8-K Inmune Bio, Inc. For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | -1.51% | -4.11% | |
| INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease | Press release | GlobeNewswire | +0.73% | -10.37% | |
| INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB | Press release | GlobeNewswire | +0.97% | +3.23% | |
| Form 8-K Inmune Bio, Inc. For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -2.23% | -10.06% | |
| INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives | Press release | GlobeNewswire | +0.00% | +7.78% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INMB section they belong to.
Where else INMB is measured.
INMB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is INmune Bio Inc. - Common stock's median reaction calculated?
Every labeled INMB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 286 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of INMB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INMB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.